Occult hepatitis B in persons infected with HIV is associated with low CD4 counts and resolves during antiretroviral therapy

Journal of Medical Virology

Volumn 81, Issue 3, 2009, Pages 441-445

  Cohen Stuart, James W T ^a   Velema, Marieke ^b   Schuurman, Rob ^a   Boucher, Charles A B ^a   Hoepelman, Andy I M ^b  

^a UNIVERSITY MEDICAL CENTER UTRECHT   (Netherlands)

^b UNIVERSITY MEDICAL CENTER UTRECHT   (Netherlands)

Author keywords

CD4; HAART; Hepatitis B; HIV; Immune reconstitution

Indexed keywords

ALANINE AMINOTRANSFERASE; ASPARTATE AMINOTRANSFERASE; EFAVIRENZ; HEPATITIS B SURFACE ANTIBODY; INDINAVIR; LAMIVUDINE; LOPINAVIR; RITONAVIR; VIRUS DNA; VIRUS RNA; ZIDOVUDINE; HEPATITIS B CORE ANTIGEN; HEPATITIS B SURFACE ANTIGEN;

ADULT; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ARTICLE; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; CD4 LYMPHOCYTE COUNT; CONTROLLED STUDY; FEMALE; FOLLOW UP; HEPATITIS B; HEPATITIS C; HEPATITIS C VIRUS; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTED PATIENT; MAJOR CLINICAL STUDY; MALE; PREVALENCE; REAL TIME POLYMERASE CHAIN REACTION; RISK FACTOR; BLOOD; CD4+ T LYMPHOCYTE; HEPATITIS B VIRUS; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IMMUNOLOGY; ISOLATION AND PURIFICATION; LIVER FUNCTION TEST; METHODOLOGY; MIDDLE AGED; PLASMA; POLYMERASE CHAIN REACTION; VIROLOGY; VIRUS LOAD;

HEPATITIS B VIRUS; HEPATITIS C VIRUS;

ADULT; ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; CD4 LYMPHOCYTE COUNT; CD4-POSITIVE T-LYMPHOCYTES; DNA, VIRAL; FEMALE; HEPATITIS B; HEPATITIS B CORE ANTIGENS; HEPATITIS B SURFACE ANTIGENS; HEPATITIS B VIRUS; HIV INFECTIONS; HUMANS; LIVER FUNCTION TESTS; MALE; MIDDLE AGED; PLASMA; POLYMERASE CHAIN REACTION; PREVALENCE; RISK FACTORS; VIRAL LOAD;

EID: 60049088902     PISSN: 01466615     EISSN: 10969071     Source Type: Journal    
DOI: 10.1002/jmv.21422     Document Type: Article

References (23)

1. Colin JF, Cazals-Hatem D, Loriot MA, Martinot-Peignoux M, Pham BN, Auperin A, Degott C, Benhamou JP, Erlinger S, Valla D, Marcellin P. 1999. Influence of human immunodeficiency virus infection on chronic hepatitis B in homosexual men. Hepatology 29:1306.
2. Filippini P, Coppola N, Pisapia R, Scolastico C, Marrocco C, Zaccariello A, Nacca C, Sagnelli C, De Stefano G, Ferraro T, De Stefano C, Sagnelli E. 2006. Impact of occult hepatitis B virus infection in HIV patients naive for antiretroviral therapy. AIDS 20:1253.
3. Gilson RJ, Tedder RS, Weller IV. 1989. Hepatitis B: Reactivation or reinfection associated with HIV-1 infection. Lancet 2:1330.
4. Gilson RJ, Hawkins AE, Beecham MR, Ross E, Waite J, Briggs M, McNally T, Kelly GE, Tedder RS, Weller IV. 1997. Interactions between HIV and hepatitis B virus in homosexual men: Effects on the natural history of infection. AIDS 11:597.
5. Goncales FL, Jr., Pereira JS, Da Silva C, Thomaz GR, Pavan MH, Fais VC, Magna LA, Goncales NS. 2003. Hepatitis B virus DNA in sera of blood donors and of patients infected with hepatitis C virus and human immunodeficiency virus. Clin Diagn Lab Immunol 10:718.
6. Guido M, Thung SN, Fattovich G, Cusinato R, Leandro G, Cecchetto A, Cesaro S, Panese P, Rugge M. 1999. Intrahepatic expression of hepatitis B virus antigens: Effect of hepatitis C virus infection. Mod Pathol 12:599.
7. Haverkamp M, Smit M, Weersink A, Boucher CA, Hoepelman AI. 2003. The effect of lamivudine on the replication of hepatitis B virus in HIV-infected patients depends on the host immune status (CD4 cell count). AIDS 17:1572.
8. Hofer M, Joller-Jemelka HI, Grob PJ, Luthy R, Opravil M. 1998. Frequent chronic hepatitis B virus infection in HIV-infected patients positive for antibody to hepatitis B core antigen only. Swiss HIV Cohort Study. Eur J Clin Microbiol Infect Dis 17:6.
9. Lai CL, Dienstag J, Schiff E, Leung NW, Atkins M, Hunt C, Brown N, Woessner M, Boehme R, Condreay L. 2003. Prevalence and clinical correlates of YMDD variants during lamivudine therapy for patients with chronic hepatitis B. Clin Infect Dis 36:687.
10. Neau D, Winnock M, Jouvencel AC, Faure M, Castera L, Legrand E, Lacoste D, Ragnaud JM, Dupon M, Fleury H, Lafon ME, Dabis F. 2005. Occult hepatitis B virus infection in HIV-infected patients with isolated antibodies to hepatitis B core antigen: Aquitaine cohort, 2002-2003. Clin Infect Dis 40:750.
11. Nunez M, Rios P, Perez-Olmeda M, Soriano V. 2002. Lack of 'occult' hepatitis B virus infection in HIV-infected patients. AIDS 16:2099.
12. Pas SD, Fries E, De Man RA, Osterhaus AD, Niesters HG. 2000. Development of a quantitative real-time detection assay for hepatitis B virus DNA and comparison with two commercial assays. J Clin Microbiol 38:2897.
13. Pastore G, Santantonio T, Monno L, Milella M, Luchena N, Angarano G. 1988. Effects of HIV superinfection on HBV replication in a chronic HBsAg carrier with liver disease. J Hepatol 7:164.
14. Pogany K, Zaaijer HL, Prins JM, Wit FW, Lange JM, Beld MG. 2005. Occult hepatitis B virus infection before and 1 year after start of HAART in HIV type 1-positive patients. AIDS Res Hum Retroviruses 21:922.
15. Raimondo G, Pollicino T, Cacciola I, Squadrito G. 2007. Occult hepatitis B virus infection. J Hepatol 46:160.
16. Ratto-Kim S, Garner RP, Kim JH, Jagodzinski LL, Michael NL, Paris R, Redfield RR, Birx DL. 2004. Prospective analyses of HIV-1-specific proliferative responses, recall antigen proliferative responses, and clinical outcomes in an HIV-1-seropositive cohort. J Infect Dis 189:1988.
17. Re VL III, Frank I, Gross R, Dockter J, Linnen JM, Giachetti C, Tebas P, Stern J, Synnestvedt M, Localio AR, Kostman JR, Strom BL. 2007. Prevalence, risk factors, and outcomes for occult hepatitis B virus infection among HIV-infected patients. J Acquir Immune Defic Syndr 44:315.
18. Rodriguez-Torres M, Gonzalez-Garcia J, Brau N, Sola R, Moreno S, Rockstroh J, Smaill F, Mendes-Correa MC, DePamphilis J, Torriani FJ. 2007. Occult hepatitis B virus infection in the setting of hepatitis C virus (HCV) and human immunodeficiency virus (HIV) co-infection: Clinically relevant or a diagnostic problem? J Med Virol 79:694.
19. Santos EA, Yoshida CF, Rolla VC, Mendes JM, Vieira IF, Arabe J, Gomes SA. 2003. Frequent occult hepatitis B virus infection in patients infected with human immunodeficiency virus type 1. Eur J Clin Microbiol Infect Dis 22:92.
20. Sengupta S, Rehman S, Durgapal H, Acharya SK, Panda SK. 2007. Role of surface promoter mutations in hepatitis B surface antigen production and secretion in occult hepatitis B virus infection. J Med Virol 79:220.
21. Shire NJ, Rouster SD, Stanford SD, Blackard JT, Martin CM, Fichtenbaum CJ, Sherman KE. 2007. The prevalence and significance of occult hepatitis B virus in a prospective cohort of HIV-infected patients. J Acquir Immune Defic Syndr 44:309.
22. Vento S, Di Perri G, Luzzati R, Cruciani M, Garofano T, Mengoli C, Concia E, Bassetti D. 1989. Clinical reactivation of hepatitis B in anti-HBs-positive patients with AIDS. Lancet 1:332.
23. Wagner AA, Denis F, Weinbreck P, Loustaud V, Autofage F, Rogez S, Alain S. 2004. Serological pattern 'anti-hepatitis B core alone' in HIV or hepatitis C virus-infected patients is not fully explained by hepatitis B surface antigen mutants. AIDS 18:569.